TY  - JOUR
A1  - Lapa, Constantin
A1  - Kircher, Malte
A1  - Hänscheid, Heribert
A1  - Schirbel, Andreas
A1  - Grigoleit, Götz Ulrich
A1  - Klinker, Erdwine
A1  - Böck, Markus
A1  - Samnick, Samuel
A1  - Pelzer, Theo
A1  - Buck, Andreas K
T1  - Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
JF  - Theranostics
N2  - Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.

Methods: 
We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.

Results: 
PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.

Conclusion: 
Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.
KW  - peptide receptor
KW  - PRRT
KW  - sarcoidosis
KW  - somatostatin receptors
KW  - radionuclide therapy
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158983
VL  - 8
IS  - 3
ER  - 
TY  - JOUR
A1  - Schossee, Nadine
A1  - Veit, Gabriele
A1  - Gittel, Julia
A1  - Viebahn, Johannes
A1  - Niklaus, Marius
A1  - Klingler, Philipp
A1  - Üçeyler, Nurcan
A1  - Klinker, Erdwine
A1  - Kobsar, Anna
A1  - Boeck, Markus
A1  - Koessler, Juergen
T1  - Profile of the single-use, multiple-pass protein A adsorber column in immunoadsorption
JF  - Vox Sanguinis
N2  - Background and Objectives
Immunoadsorptions (IA) are used to remove autoantibodies from the plasma in autoimmune disorders. In this study, we evaluated the effects of a single-use, recombinant staphylococcal protein A-based immunoadsorber on blood composition of the patient.

Materials and Methods
In a cohort of patients with myasthenia gravis or stiff-person syndrome, essential parameters of blood cell count, coagulation, clinical chemistry or plasma proteins and immunoglobulins (Ig) were measured before and after IA (n = 11).

Results
In average, IA reduced the levels of total IgG, IgG1, IgG2 and IgG4 by approximately 60%, the acetylcholine receptor autoantibody levels by more than 70%. IgG3, IgA or IgM were diminished to a lower extent. In contrast to fibrinogen or other coagulation factors, the column markedly removed vitamin K-dependent coagulation factors II, VII, IX and X by approximately 40%–70%. Accordingly, international normalized ratio and activated partial thromboplastin time were increased after IA by 59.1% and 32.7%, respectively. Coagulation tests almost returned to baseline values within 24 h. Blood cell count, electrolytes, total protein or albumin were not essentially affected. No clinical events occurred.

Conclusion
The single-use, multiple-pass protein A adsorber column is highly efficient to remove IgG1, IgG2 and IgG4 or specific acetylcholine receptor autoantibodies from the plasma. Coagulation parameters should be monitored, since the column has the capacity to largely reduce vitamin K-dependent factors.
KW  - plasma
KW  - apheresis technologies
KW  - apheresis-therapeutic
KW  - blood processing
KW  - haemostasis
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259689
VL  - 117
IS  - 3
ER  -